Hey there! Welcome!
Get updated on
Select Speciality
Top Picks
13 Nov, 26
AHA 2026
The sessions presented at AHA 2026, underscore the importance of secondary prevention in MI patients and focus on the benefits of beta-blocker treatment and reperfusion treatment in these patients.
12 Nov, 26
AHA 2026
The AHA highlights focus on risk-guided intensive BP control, novel aldosterone synthase inhibitors, GLP-1RA–mediated BP reduction, digital BP management, and real-world combination therapy outcomes.
17 Nov, 26
Eur J Prev Cardiol.
- Elevated remnant cholesterol [≥1 mmol/L (39 mg/dL)] was more prevalent in familial hypercholesterolemia (FH) population (12%-78%) vs non-FH individuals (11%-12%)
- Across CGPS & UK Biobank, remnant cholesterol ≥1 mmol/L was associated with higher CAD risk in FH (HRs 1.14-1.60) & non-FH subjects (HR 1.47-1.49), conferring an approximately 50% additional CAD risk beyond lifelong LDL-C elevation in FH individuals.
17 Nov, 26
A 20-month-old girl developed blistering after amoxicillin therapy, with characteristic “string-of-pearls” lesions. Persistent blistering despite initial treatment required escalation for refractory linear IgA bullous dermatosis. Click here to read the treatment.
17 Nov, 26
A 35-year-old woman with ESRD on maintenance hemodialysis experienced recurrent decompensated HFrEF (LVEF 28%), with severe MR and TR, and pulmonary hypertension despite medical therapy. Click here to read the treatment.
16 Nov, 26
BMC Pedia
- Using hemoglobin and serum ferritin , normal iron status was observed in 82-90% of infants during the first year.
- Iron deficiency prevalence increased from 5.6-11.5% (Hb+SF) to 20.2-27.7% when zinc protoporphyrin (ZnPP) was included.
- Anemia affected 4.5-7.7% of infants; >50% of cases were non-iron deficiency anemia (non-IDA), and biomarker agreement was low.
Featured

12 Nov, 26

26 Oct, 26

26 Oct, 26






















